Prognostic Factors of Takigawa et al for a Patient with Advanced Non-Small Cell Lung Cancer (NSCLC)

Description

Takigawa et al identified prognostic factors associated with survival in patients with advanced non-small cell lung cancer (NSCLC). This can help identify patients who may benefit from aggressive or more novel therapies. The authors are from National Shikoku Cancer Center Hospital in Matsuyama, Japan.

Patient selection:

(1) non-small cell lung cancer

(2) advanced disease

(3) ECOG performance scale 0 to 3

Non-small cell lung cancer includes:

(1) squamous cell carcinoma

(2) adenocarcinoma

(3) large cell undifferentiated carcinoma

Advanced disease includes locally advanced disease (Stage III) and metastatic disease (Stage IV).

Parameters identified by multivariate analysis:

(1) ECOG performance scale (PS)

(2) Stage

(3) hemoglobin

(4) unintended weight loss

ECOG PS	Stage	Hemoglobin	Weight Loss	Group
0 or 1	III	> 11 g/dL	NA	I
0 or 1	III	<= 11 g/dL	NA	II
0 or 1	IV	NA	NA	II
2 or 3	NA	NA	< 5%	II
2 or 3	NA	NA	>= 5%	III

Group	Median Survival	Percent 1 Year Survival	Percent 2 Year Survival
I	95 weeks	68%	46%
II	39 weeks	38%	13%
III	17 weeks	4%	0%

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10